Effect of Intranasal Vasopressin on Cooperative Behavior in Schizophrenia
NCT ID: NCT04190004
Last Updated: 2019-12-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2018-01-01
2018-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
vasopressin
All subjects will receive bot 40IU of vasopressin and saline placebo in counterbalanced design
Vasopressins
40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
Placebo
All subjects will receive bot 40IU of vasopressin and saline placebo in counterbalanced design
Placebo
40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vasopressins
40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
Placebo
40 International units of vasopressin or placebo will be given intra-nasally. The order of the administration will be counterbalanced
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed as Schizophrenia or Schizophreniform disorder as per DSM IV TR
* At least 7 years of formal education
* MOCA score \>24
Exclusion Criteria
* Substance dependence in the past 12 months, excluding nicotine dependence
* Current comorbid axis 1 psychiatric disorder
* Hypersensitivity or previous allergy to Vasopressin
* Serious medical or neurological illness which may interfere with assessment and administration of vasopressin
* Hypertension
* Impaired renal functions based on serum creatinine above 1.5
* Electrolyte imbalance
* Receiving ECT or has received ECT in the past 8 weeks
* Clinical history of mental retardation
* Pregnancy • Lactation
* Risk of harm to self or others
* Any significant nasal pathology which may hinder the intranasal absorption of the drug
* Hearing or visual impairment that significantly affects the comprehension and execution of the study
18 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Mental Health and Neuro Sciences, India
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Naren P Rao
Additional Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institute of Mental Health and Neurosciecnes
Bangalore, Karnataka, India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IEC/2017
Identifier Type: -
Identifier Source: org_study_id